Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study-Reference-Cited by-同舟云学术

Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study

Published:2021-10 Issue: Volume:111 Page:281-287
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Bhushan B L Shashi,Wanve Sunil,Koradia Parshottam,Bhomia Vinay,Soni Pravin,Chakraborty Sisir,Khobragade Akash,Joshi Shashank,Mendiratta Sanjeev Kumar,Kansagra Kevin Kumar,Parihar Anurag,Sharma Sunil,Patel Jatin

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference25 articles.

1. Early administration of oral oseltamivir increases the benefits of influenza treatment;Aoki;J Antimicrob Chemother,2003

2. Autoantibodies against type I IFNs in patients with life-threatening COVID-19;Bastard;Science,2020

3. Remdesivir for the treatment of COVID-19 – final report;Beigel;N Engl J Med,2020

4. Imbalanced host response to SARS-CoV-2 drives development of COVID-19;Blanco-Melo;Cell,2020

5. Clinical course of severe and critically ill patients with coronavirus disease 2019 (COVID-19): a comparative study;Chen;J Inf Secur,2021

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A fusion protein approach to integrate antiviral and anti-inflammatory activities for developing new therapeutics against influenza A virus infection;Antiviral Research;2024-08

2. A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19;Infectious Diseases and Therapy;2024-05-21

3. Harnessing the power of IFN for therapeutic approaches to COVID-19;Journal of Virology;2024-05-14

4. Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities;Advances in Therapy;2023-11-27

5. More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients;Frontiers in Immunology;2023-11-21